Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28

Peptide manufacturing vertical on track to begin generating revenue in August 2026; VectorMist™ 510(k) submission advancing toward FDA filing

MEQUON, Wis., July 24, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the filing of its first quarterly financial statements and Management's Discussion & Analysis since completing its going-public transaction through a reverse takeover with OpenSesame Acquisition Corp. on April 23, 2026. The full filings are available under the Company's profile on SEDAR+ at www.sedarplus.ca.